Combination Therapy of Prostate/Breast Cancer: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Oncology | Radiology, Nuclear Medicine & Medical Imaging
Contributor:
Tyrillshall Damiana

Combinations of radionuclide therapy (RT) and targeted radionuclide therapy (TRT) with other therapies with distinct mechanisms of action represent a promising strategy. As for prostate cancer and breast cancer, the two most prevalent cancer types worldwide, several combination-based therapies have been evaluated. 

  • combination therapy
  • targeted radionuclide therapy
  • peptide receptor radionuclide therapy
  • radionuclide therapy
  • prostate cancer
  • breast cancer

1. Introduction

Radionuclide therapy (RT) involves the use of radionuclides that target specific cellular processes or accumulate in cancer cells because of their chemical properties [1]. Targeted radionuclide therapy (TRT) uses radiotracers that target molecules that are overexpressed on cancer cells. These radiotracers roughly consist of two main components, a targeting agent and a radionuclide [2]. The targeting agent can be, for example, an antibody, a natural or synthetic ligand, or a nanobody that can be coupled via a chelator to a radionuclide. There are different types of radionuclides used in medicine and biological research: those who emit α-particles (e.g., 223Ra, 212Bi, 213Bi, 225Ac, and 227Th), β−-particles (e.g., 67Cu, 90Y, 131I, 177Lu, 186Re, and 188Re), β+-particles (e.g., 11C, 13N, 15O, 68Ga, and 18F), auger electrons (e.g., 111In and 125I), and γ-emitters (e.g., 67Cu, 177Lu, and 111In) [3][4][5]. Radionuclides that emit β+-particles and γ-emitters are used in nuclear imaging. Besides, some of these radionuclides can emit both imaging photons and therapeutic particles (e.g., 177Lu and 67Cu). The selection of the optimal radionuclide for both imaging and treatment among other factors depends on the pharmacokinetic properties of the radiotracer. In addition, for treatment options, the type and stage of the disease are also important factors that need to be taken into consideration. In the treatment of large tumors, for example, β−-emitters are considered the ideal radionuclide. These β−-emitters have a long track length and therefore neighboring tumor cells that lack expression of the targeted molecules are also exposed to radiation, the so-called “cross-fire” effect [6][7]. For the treatment of micro-metastasis and small clusters of cancer cells, α-emitters, and auger electron-emitters are considered to be beneficial due to their short range and high-energy which results in a high level of cytotoxicity [8].
The broad option of targeting agents, together with the wide range of radionuclides with unique properties, allows radiotracers to be designed for targeting different types of cancers at different disease stages. Furthermore, a unique feature of RT and TRT is the ability to determine the radiation dose that reaches the tumor and healthy tissues, which can be assessed and correlated with efficacy and toxicity, respectively.
Besides having the most optimal radiopharmaceutical, for the treatment to be effective, several other factors should also be considered, including the cumulative radiation dose delivered, tissue and dose penetration, and the density of the targeted molecule on cancer cells. The delivery of radiopharmaceuticals might not always reach their target as desired due to heterogeneous expressions of the molecular marker that the radiotracer is designed to target and poor vasculature of the tumor [9]. Furthermore, studies have reported changes in radiosensitivity as well as a decrease in expression of the targeted molecule during disease progression and after exposure to other anti-cancer therapies [10][11][12][13][14][15][16]. The above-mentioned factors can greatly impact the success of RT and TRT, and as a consequence, novel strategies are needed to improve the treatment efficacy of RT and TRT. One promising strategy includes the combination of RT and TRT with other anti-cancer therapeutics that have shown promising results in tumor management [17].

2. Prostate and Breast Cancer

PCa is the second most diagnosed cancer among men with an estimated 1,276,106 new cases and 358,989 deaths worldwide in 2018 [18]. The estimated PCa incidence and mortality rates per 100,000 males in 2018 were 29.3 and 7.6, respectively. For early detection of PCa, men at risk and between the age of 55–69 are recommended by their physician to be screened for PCa. The prostate-specific antigen (PSA) blood test is currently the first-line screening method used. Abnormal results of this screening are followed by prostate biopsy or multiparametric magnetic resonance imaging for further diagnosis [19][20]. Multiple treatment options exist for men diagnosed with PCa. These treatments are based on the stage and the grade of the tumor. Localized cancers are classified into three risk groups; low, medium, and high risk based on the Gleason score. Men with low-risk PCa are managed by “active surveillance” or “watchful waiting” while high-risk cancers receive more aggressive treatments such as surgery and radiation-based therapy. In advanced metastatic PCa, initial treatments include androgen deprivation therapy (ADT) and in some cases ADT in combination with chemotherapy. Besides these, several RT and TRT agents have been or are being investigated for the treatment of metastatic PCa [20][21][22]. A few RT agents have been accepted for clinical use, for example, 223Ra-dichloride and 153Sm-lexidronam for the treatment of metastatic castration-resistant PCa (mCRPCa) with bone metastases [23][24]. 223Ra-dichloride and 153Sm-lexidronam are both bone targeting agents that accumulate at sites with a high osteoblastic activity where they cause DNA damage in tumor cells [25][26]. Even though no TRT agents have been clinically approved for PCa treatment yet, preclinical and clinical studies show promising results. Among the TRT agents studied for PCa treatment, agents targeting the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPR) are the most well-known.
In females, breast cancer (BC) is the most diagnosed cancer and the leading cause of cancer death. There were an estimated 2,088,849 new cases and 626,679 deaths as a consequence of BC worldwide in 2018 [18]. For the early detection of BC, women at the age of 50 are recommended to be screened. Women at risk or who carry BRCA1 or BRCA2 mutations are advised to be screened as early as 40 years of age. The screening includes both physical breast examination as well as mammographic imaging. Abnormal results of these screenings are followed by biopsy for further diagnosis [27]. Both tumor morphologic characteristics and molecular factors are critical for treatment decisions in BC [28]. The disease is very heterogeneous and consists of multiple biological subtypes: luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-driven, and basal-like tumors [29][30][31][32]. Among other molecular factors, these subtypes can to some extent be identified by estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, markers that majorly impact the treatment and prognosis of the disease. Luminal A tumors and luminal B tumors are either ER or PR positive, or both ER- and PR-positive. However, luminal A tumors either have higher ER- or PR-expression, or both, compared to luminal B tumors. Furthermore, luminal A tumors are HER2 negative, while luminal B tumors have variable HER2 expression. HER2-driven tumors are usually either ER- or PR-negative, or both ER- and PR-negative, and always HER2-positive. Basal-like tumors are the most aggressive subtype. These tumors are ER-, PR-, and HER2-negative, and are also known as triple-negative BC (TNBC). Tumors that are either ER- or PR-positive, or both ER- and PR-positive, are treated with endocrine therapy alone or in combination with chemotherapy [33]. Patients with either ER- or PR- positive, and HER2-positive tumors benefit more from a combination of hormone and anti-HER2 therapy, while TNBC tumors are treated with chemotherapy [32]. Unfortunately, treatment for metastatic BC remains a challenge. Currently, several markers including HER2, GRPR, and somatostatin receptors (SSTR) are being investigated as possible targets for TRT in the treatment of metastatic BC. Up to now, none of these TRT treatments have been approved for clinical use. Table 1 shows a selection of RT and TRT agents clinically used or preclinically/clinically studied for PCa and BC treatment.
Table 1. Selection of RT and TRT agents on the market or under development for the treatment of PCa and BC.

Agent

Type of Cancer

Target

Disease Stage

Development Phase

Trial Name or Registration Number

Ref.

Radionuclide therapy

          

223Ra chloride

PCa

Calcium analog

Bone metastasis

Commercially available

-

[34]
 

BC

    

Clinical study

-

[35]

153Sm-lexidronam

PCa/ BC

Binding to hydroxyapatite matrix

Bone metastasis

Commercially available

-

[36]

Targeted radionuclide therapy

          

177Lu-PSMA-617

PCa

PSMA

mCRPCa

Phase III; active, not recruiting

NCT03511664

  

227Th- PSMA-TTC

PCa

PSMA

mCRPCa

Phase I; recruiting

NCT03724747

  

177Lu-PSMA/CTT1403

PCa

PSMA

mCRPCa

Phase I; active, not recruiting

NCT03822871

  

177Lu-PSMA-R2

PCa

PSMA

mCRPCa

Phase I/II; recruiting

NCT03490838

  

177Lu-J591/TLX591/ 177Lu-DOTA-Rosopatamab

PCa

PSMA

mCRPCa

Clinical study

-

[37]

225Ac-PSMA-617

PCa

PSMA

mCRPCa

Clinical study

-

[38][39]

177Lu-NeoB, formerly known as 177Lu-NeoBOMB1

PCa

GRPR

Under investigation

Phase I/II; Recruiting

NCT03872778

  

177Lu-NeoB/NeoBOMB1

PCa, BC

GRPR

Under investigation

Preclinical study

-

[40][41]

177Lu-RM2

PCa

GRPR

mCRPCa

Clinical study

-

[42]

177Lu-DOTA0-Tyr3-Octreotate and 177Lu-DOTA-JR11

BC

SSTR

Under investigation

Preclinical study

-

[43]

188Re-trastuzumab

BC

HER2

Under investigation

Preclinical study

-

[44]

RT: radionuclide therapy, TRT: targeted radionuclide therapy, PCa: prostate cancer, BC: breast cancer, PSMA: prostate-specific membrane antigen, GRPR: gastrin releasing peptide receptor, SSTR: somatostatin receptor, HER2: human epidermal growth factor receptor 2, mCRPCa: metastatic castration-resistant prostate cancer.

3. Hormone Therapy-Based Combination Therapy

A key feature of PCa is its hormone responsiveness. The growth of PCa cells is usually dependent on androgens. This was observed first by Huggins and Hodges in 1941 [45]. Since then, ADT has become the primary treatment option for men with advanced metastatic PCa. Several strategies of ADT exist for the treatment of PCa. These strategies are classified into two groups, surgical castration, and medical/chemical castration. Surgical castration is achieved by orchiectomy, a surgical procedure in which one or both testicles are removed. However, its use is not so frequent and declining. Medical castration includes the use of anti-androgens (e.g., bicalutamide, flutamide), androgen synthesis inhibitors (e.g., abiraterone, enzalutamide), and luteinizing hormone-releasing hormone (LHRH) agonists and antagonists (e.g., leuprolide acetate, goserelin). Anti-androgens and drugs that target LHRH receptors represent first and second generations of ADT options. Androgen pathway inhibitors represent the third-generation of ADT drugs [46]. ADT is typically the first systemic treatment after local treatment options have become insufficient, although it is also used as neoadjuvant therapy for local radiation therapy and surgery [47][48][49].
Studies have shown that blockage of androgen can make tumors more radiosensitive. The radiosensitizing effect of ADT can occur through several mechanisms including cell cycle checkpoint inhibition, DNA damage repair pathway, and transcriptional changes in expression of DNA repair genes [50][51][52]. This provides a rationale for combining ADT with RT or TRT.
Once initiated, ADT is generally continued throughout the course of PCa treatment, including during metastatic PCa. Among other sites, bone is one of the most frequent metastatic target sites for PCa. It was reported that 90% of patients with metastatic PCa will develop bone metastasis [53]. The consequences are devastating, and the available treatment options are limited. Currently, 223Ra-dichloride is being used for the treatment of bone metastases [54]. However, patients continue to receive hormone therapy as well. A clinical study showed that 223Ra (50 kBq/kg) can be safely combined with abiraterone or enzalutamide for the treatment of bone metastasis. In this study, the addition of abiraterone or enzalutamide to 223Ra therapy demostrated prolonged median survival in patients with mCRPCa [55]. However, recently one study showed an increased incidence of fractures and deaths in patients who received 223Ra (55 kBq/kg) combined with abiraterone, compared with patients who received abiraterone alone [56]. The toxicity profiles of enzalutamide in combination with 223Ra are consistent with those seen when they are used as single agents. However, skeletal-related events of this combination are still under investigation (NCT02225704).
In a preclinical setting, LNCap cells treated in vitro with abiraterone or enzalutamide showed increased expression of PSMA which was linked to an antiproliferative effect. Interestingly, another cell line that is androgen-independent also increased its PSMA expression after abiraterone and enzalutamide treatment. However, in this case, no antiproliferative effect was observed [57]. Thus, patients especially those with advanced PCa who receive ADT may benefit from a combination of abiraterone or enzalutamide and PSMA-targeting radiotracers. In line with this Moo, T.A., et al., 2017 recently observed a seven-fold increase in 68Ga-PSMA-11 uptake in patients after receiving ADT [58]. Even though the PSMA radiotracer was used for imaging purposes in this study, these findings indicate the high potential of combination therapy when a PSMA radiotracer coupled to a therapeutic radionuclide is applied.
In BC, hormone therapy is given to patients whose tumors express ER, PR, or both. The purpose of hormone therapy is to prevent the interaction between estrogens and estrogen-dependent pathways that stimulate the proliferation of neoplastic cells. This can be performed by blocking the production of estrogens or by blocking the interaction between estrogen and cancer cells. The production of estrogen can be blocked by oophorectomy, aromatase inhibitors (e.g letrozole), or LHRH analogs (e.g., goserelin). The activity of estrogen towards tumor cells can be blocked using a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down regulator (SERD) such as tamoxifen and fulvestrant, respectively [59][60].
Studies suggest that the cross-talk between estrogen and growth-factor signal cascades might inhibit the effects of radiation. Hence blockage of estrogen and thereby its cross-talk with growth-factor signal cascades can potentially make tumors more radiosensitive, providing reasoning for combining anti-estrogen treatment with RT or TRT [61].
Hormonal therapy is the first-line treatment for hormone-positive metastatic BC. As in PCa, in BC bone is also the most preferential metastatic site, and 223Ra in combination with hormone therapy is becoming more apparent in the treatments of bone metastasis in BC as well. A phase II study that evaluated the efficacy of 223Ra in combination with hormone therapy for the treatment of hormone-positive BC with bone metastases found a high disease control rate at nine months (49%) and tumor response rate at six months (54%) [62]. In this study, patients received 223Ra (55 kBq/kg) every four weeks up to six cycles and a hormonal agent, either tamoxifen or fulvestrant. In addition, these patients also received a subcutaneous injection of denosumab, a monoclonal antibody used for the treatment of osteoporosis, every four weeks, which was considered standard of care during the study period.
Interestingly, trastuzumab, an anti-HER2 in combination with 177Lu-DOTAGA-PEG2-RM26, a GRPR TRT, has been shown to prolong overall survival in mice bearing the human PCa PC3 xenograft [63]. This combination therapy strategy might also be interesting for targeting HER2 positive BC that are also ER or PR positive since it is known that this BC subtype often also expresses the GRPR [64][65][66].

4. Chemotherapy-Based Combination Therapy

There are several types of chemotherapeutic agents used to treat cancer. These drugs can be categorized based on their chemical structure and their mechanism of action. Some of these drugs target different phases of the cell cycle while others are cell-cycle non-specific (Figure 1) [67]. Alkylating agents and platinum derivatives (e.g., cyclophosphamide and cisplatin, respectively) are active in the resting phase of the cell. These types of agents are therefore considered cell-cycle non-specific. Alkylating agents substitute alkyl groups for hydrogen atoms or bind to DNA causing crosslink formation within DNA double strands and thereby stop tumor growth. Platinum derivatives also cause crosslinking of DNA but do not alkylate [68]. Antimetabolites (e.g., 5-fluorouracil) block cellular metabolism by mimicking normal substances within the cell [69]. Anthracyclines (e.g., doxorubicin) act during multiple phases of the cell-cycle including during DNA replication [70]. Topoisomerase inhibitors (e.g., topotecan) are types of chemotherapy drugs that interfere with the action of topoisomerase enzymes (topoisomerase I and II). These enzymes are involved in the separation of DNA strands before DNA replication [71]. Plant alkaloids such as taxanes (e.g., paclitaxel and docetaxel) act during different phases of the cell cycle and are well-established cancer treatment options for both PCa and BC [71].
Pharmaceutics 13 00674 g001 550
Figure 1. Cell-cycle and respective sensitivity to chemotherapeutic agents. G0; Gap 0 phase, G1: Gap 1 phase, G2: Gap 2 phase, S: Synthesis phase, M: Mitosis phase.
Understanding how chemotherapies work has helped scientists predict which drugs or therapies may be combined successfully. The combination of chemotherapy and radiotherapy has long been used in the treatment of several types of cancers [72][73][74][75][76]. The effect of this combination occurs through several mechanisms [67]. Chemotherapy and radiation can both induce DNA damage. Single strand breaks (SSBs) in the DNA caused by these therapies individually can normally be repaired rapidly. However, radiation-induced SSBs in the DNA can become more difficult to repair with the addition of chemotherapeutic agents such as alkylating agents and platinum derivatives, because DNA crosslinking caused by these chemotherapeutics hinder DNA damage repair. Furthermore, chemotherapeutic agents that effect nucleoside and nucleotide metabolism can inhibit post-radiation DNA damage repair. Moreover, agents such as taxanes exert their cytotoxic activity by preventing microtubule disassembly during the G2/M phase of the cell cycle, causing cell arrest. During these phases, cells are more radiosensitive because endogenous radioprotectors molecules are at their lowest. In addition, chemotherapies that target the S phase of the cell cycle and those that inhibit either proliferation, growth factor pathways, or both, may be effective in preventing tumor cell repopulation after radiotherapy, which is one of the crucial factors determining cure probability in radiotherapy [77][78]. Another benefit that chemotherapy brings when used in combination with radiotherapy is its ability to make hypoxic cells more radiosensitive. Tumor radiosensitivity rapidly decreases in hypoxic environments. The presence of oxygen can prevent repair of the DNA damage (oxygen makes the DNA damage permanent), the so-called “oxygen-enhancement effect”. This means that in hypoxic conditions, higher radiation doses are required to achieve the same biologic effect as in the presence of oxygen [79]. Chemotherapy can reoxygenate tumors by removing cells from the tumor allowing hypoxic cell to have more access to oxygen, and thus making them more sensitive to radiation [80][81].
As for RT and TRT, similar interactions to the above mentioned are expected. However, these might vary since the characteristics of RT and TRT (heterogeneous irradiation, long exposure, and low absorbed dose rate) differ from those of conventional radiotherapy (homogeneous irradiation, short exposure, and high absorbed dose rate) [82]. Nevertheless, there is growing evidence that supports the benefits of chemotherapy combined with RT or TRT. In an in vitro study, the combination of cisplatin and 186Re-HEDP (1.84 or 3.69 MBq/mL), a bone targeting agent, showed a synergetic effect in the treatment of R3327-MATLyLu cells [83]. These are metastatic anaplastic tumor (MAT) cells with high metastatic potential to the lymph nodes and lungs (LyLu) derived from the Dunning rat R3327 [84]. 186Re-HEDP and cisplatin alone both cause a decrease in the number of surviving tumor cells, and the combination of the two showed a greater effect in a dose dependent manner. The benefits of cisplatin in combination with bone targeting RT were later confirmed by a randomized clinical trial using 89Sr instead of 186Re-HEDP. They found that low-doses of cisplatin combined with 89Sr (148 MBq) significantly improved the quality of life and the duration of metastatic bone pain reduction in patients with CRPCa [85]. Pain relief was observed in 91% of the patients who received combination therapy and 63% in the placebo group with a median duration of 120 and 60 days, respectively. Furthermore, fewer new painful sites and less bone disease progression were observed when the combination therapy was administered.
Another study investigated the efficacy of docetaxel in combination with 177Lu-radiolabeled anti-Lewis Y (LeY) human monoclonal antibody hu3S193 in mice bearing LeY positive DU145 PCa xenografts [86]. The LeY antigen is a blood group-related antigen that is overexpressed in over 60–90% of human epithelial cancers [87]. Treatment of DU145 xenografts with 177Lu-hu3S193 (3.7 MBq) alone caused a moderate delay in tumor growth of about 80 days. However, mice treated with the combination of 177Lu-hu3S193 and docetaxel survived until the end of the study and had a tumor growth delay of about 140 days. The authors also investigated the effect of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 in combination with 177Lu-hu3S193. EGFR is involved in regulating cellular proliferation, differentiation, and survival, thus blockage of the EGFR is expected to cause inhibition of cell growth [88]. This combination has shown to reduce the rate of tumor growth, however, to a lower extent compared to 177Lu-hu3S193 plus docetaxel. Furthermore, in other studies, docetaxel has shown to have a radiosensitizing effect in vitro in human colon, lung, head, neck, cervical, and several PCa cell lines [89][90][91][92][93].
In BC, chemotherapy is generally recommended as the first-line treatment for patients with TNBC. Patient-related factors such as tumor biology, disease growth rate, presence of metastases, menopausal status, and comorbidities should also be considered in the decision on a specific chemotherapy [94]. Anthracyclines alone, or in combination with other agents, are among the most active chemotherapies for the treatment of BC. One study investigated the effect of a monoclonal antibody targeting the EGFR, 177Lu-anti-EGFR in combination with docetaxel, doxorubicin plus the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor rucaparib (PARP inhibitors work by inhibiting DNA repair), for the treatment of TNBC cells [95]. 177Lu-anti-EGFR (300 MBq/kg) in combination with docetaxel and doxorubicin reduced the growth rate of MDA-MB-231 and HCI-002 BC xenografts by 83 days vs. 52 days when the BC xenografts were treated with 177Lu-anti-EGFR alone. The triple-agent combination therapy resulted in full eradication of the established xenograft. Furthermore, no recurrences were observed up to 120 days for MDA-MB-231 xenografts and >195 days for HCI-002 xenografts after the triple-agent combination treatment. Further analysis suggested that inhibition of central DNA repair proteins was crucial to the efficacy of the triple-agent combination.
Recently, 177Lu-Bombesin-PLGA (paclitaxel) nanomedicine has been investigated as a potential combination therapy for BC [96]. Here the radionuclide 177Lu was coupled to the bombesin (BN) peptide which is known to have a high affinity for the GRPR. High expression of GRPR is seen in several types of cancers including BC [97]. Paclitaxel (PTX) and, 177Lu-Bombesin were both loaded onto the poly lactic-co-glycolic acid (PLGA) nanobody and studied on MDA-MB-BC cells. The chemotherapeutic effect of PTX and the radiation of 177Lu-BN (5 MBq) produced by the 177Lu-BN-PLGA(PTX) nanosystem had a synergistic effect on MDA-MB-231 cell viability compared to BN-PLGA(PTX) alone. Interestingly, internalization with regard to total uptake was higher for 177Lu-BN-PLGA(PTX) compared to 177Lu-BN alone.
Furthermore, there is an ongoing clinical trial investigating the effect of 223Ra-dichloride (55 kBq/kg) in HER2 negative, hormone-positive BC patients with bone metastases treated with exemestane and everolimus (NCT02258451). The results of this study have not been published yet.

5. Immunotherapy-Based Combination Therapy

In recent years, immunotherapy has become an important cancer treatment. Several types of immunotherapy for cancer are known including monoclonal antibodies (e.g., anti-cytotoxic T-lymphocyte-associated protein 4), checkpoint inhibitors (e.g., anti-programmed cell death protein 1 (anti-PD-1) and its ligand programmed death-ligand 1 (anti-PD-L1)), cytokines, T-cell therapy, and vaccines. Infiltration into the tumor microenvironment and successful activation of effector T lymphocytes are crucial for the success of immunotherapy. However, tumor cells have developed a variety of mechanisms to reduce anti-cancer immunity [98]. A strategy to overcome this is by combining immunotherapy with other types of therapies that make tumors more T-cell inflamed, especially in PCa and BC since the majority of these tumors are not inflamed [99][100]. Several studies have shown that depending on the type of radiotherapy, radiation can induce a tumor-specific immune response or reprogram the tumor microenvironment in a way that facilitates both immune cell recognition and immune-mediated killing [101][102][103][104]. Furthermore, radiation can also induce systemic antitumor effects in unirradiated tumors/metastases after local radiation, known as the abscopal effect [105][106][107]. The radiation-induced abscopal effect occurs through several mechanism which involves the release of a number of endogenous damage-associated molecular patterns (DAMPs) by apoptotic cells via a process termed “immunogenic cell death” (ICD). Subsequently, DAMPs triggers dendritic cells (DCs) resulting in an enhanced tumor antigen presentation, and stimulates cytotoxic T lymphocyte and the release of cytokines and chemokines which all facilitates immune response to cancer cells [107][108].
In an in vitro study, 223Ra-dichloride has been shown to enhance T cell-mediated killing of PCa (LNCap and PC3), BC (MDA-MB-231 and ZR75-1), and lung cancer (H1703 and H441) cells [109]. These cell lines were first exposed to 4 or 10 gray (Gy) of 223Ra, then co-cultured with CD8+ effector T cells specific for carcinoembryonic antigen (CEA, HLA-A2-restricted), mucin-1 (MUC-1, HLA-A2-restricted), and brachyury (HLA-A2/A24-restricted) epitopes. This resulted in a significant increase in T cell-mediated killing after both 4 and 10 Gy of radiation. Furthermore, exposure to 223Ra significantly increased the expression of calreticulin and MHC-I, both molecules that facilitate and support the initiation of anti-cancer immunity [109][110][111]. Several clinical studies have/are investigating the combination of immunotherapy with 223Ra for the treatment of PCa. These combinations are mainly focused on abrogating immunosuppression using immune checkpoint inhibitors. A phase-I randomized clinical trial evaluated the safety and tolerability of the PD-L1 checkpoint inhibitor atezolizumab when given in combination with 223Ra-dichloride (55 kBq/kg) in patients with mCRPCa (NCT02814669). Although this study is completed, no results have been published yet. In addition, a phase-II study is assessing the antigen-specific immune response of sipuleucel-T vaccine therapy with or without 223Ra (50 kBq/kg) (NCT02463799), whereas another phase-II study is investigating the combination of 223Ra plus the anti-PD-1 checkpoint inhibitor pembrolizumab as a possible treatment for castration-resistant PCa (NCT03093428).
In a preclinical study, the checkpoint inhibitor anti-PD-1 in combination with a PSMA TRT in mice bearing PCa tumor was investigated [112]. Anti-PD-1 in combination with 225Ac-PSMA-617 (30 kBq) demonstrated improved tumor control compared to the monotherapies. The time to tumor progression was 47.5 days in the combined therapy group vs. 33.5 days with anti-PD-1 or 30 days with 225Ac-PSMA-617 alone. In line with this, survival was extended to 51.5 days when animals received combination therapy vs. 37 and 32 days, respectively, when animals were treated with anti-PD-1 or 225Ac-PSMA-617 alone.
To our knowledge, there are no studies that have reported on the combination of immunotherapy with RT or TRT in BC. However, the findings gained from the studies with PCa could provide crucial insight for the development of these kinds of combination therapies for BC as well.

6. External Beam Radiation Therapy-Based Combination Therapy

Besides hormone therapy, chemotherapy, and immunotherapy, radiation therapy or radiotherapy remains an important therapeutic option for cancer treatment. About 50% of all cancer patients will receive radiotherapy of some kind throughout the period of their illness [113]. There are several types of EBRT including 3D conformal radiotherapy, intensity-modulated radiation therapy, image-guided radiotherapy, stereotactic body radiation therapy, photons radiation, and particle radiations [114]. EBRT is commonly used in everyday radiation therapy treatment. The biological effect of radiation, in general, is DNA damage. If the radiation-induced DNA damage is irreparable, the cell will eventually die during cell division. Thus, the higher the dose the higher is the chance of irreversible DNA double-strand breaks (DSBs). However, the applicable dose of EBRT is limited by the radiosensitivity of the surrounding healthy tissue. The addition of RT or TRT to EBRT offers the possibility to increase the dose applied to the solid tumor without exceeding the limitations of the surrounding normal tissues. Another advantage of this combination is that it can be directed against both localized tumors and metastases [115].
With regard to the literature, reports about EBRT in combination with RT or TRT for the treatment of PCa are rare. A phase one study investigated EBRT (8, 20, or 30 Gy) in combination with 223Ra (50 kBq/kg) in patients with hormone-refractory PCa needing EBRT due to bone pain [116]. EBRT in combination with 223Ra caused a significant reduction in bone-alkaline phosphatase concentration compared to EBRT alone. The median time to first skeletal-related events such as bone pain and bone fractures was 14 weeks in the combined treatment and 11 weeks for EBRT alone. Furthermore, overall survival was higher for patients who received EBRT in combination with 223Ra (65 weeks) compared to EBRT alone (46 weeks). Another group also observed a reduction in pain intensity in patients with mCRPCa after being treated with EBRT (8–30 Gy) in combination with another bone targeting radionuclide, 153Sm (37 MBq/kg) [117]. Toxicity profiles of this combination therapy were acceptable and fully reversible. Hematological toxicity analysis demonstrated no statistically significant differences between the combination therapy and the monotherapy in hemoglobin concentration and the number of blood cells. Other adverse events such as hypercalcemia were reported among a few candidates in both study arms, but no pathological fractures or spinal cord compression was observed in these patients.

This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics13050674

References

  1. Kassis, A.I.; Adelstein, S.J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46, 4S–12S.
  2. Yeong, C.H.; Cheng, M.H.; Ng, K.H. Therapeutic radionuclides in nuclear medicine: Current and future prospects. J. Zhejiang Univ. Sci. B 2014, 15, 845–863.
  3. Ersahin, D.; Doddamane, I.; Cheng, D. Targeted radionuclide therapy. Cancers 2011, 3, 3838–3855.
  4. Dash, A.; Chakraborty, S.; Pillai, M.R.; Knapp, F.F., Jr. Peptide receptor radionuclide therapy: An overview. CancerBiother. Radiopharm. 2015, 30, 47–71.
  5. Nayak, T.K.; Brechbiel, M.W. Radioimmunoimaging with longer-lived positron-emitting radionuclides: Potentials and challenges. Bioconjug. Chem. 2009, 20, 825–841.
  6. Marcu, L.; Bezak, E.; Allen, B.J. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Crit. Rev. Oncol. Hematol. 2018, 123, 7–20.
  7. Pouget, J.P.; Navarro-Teulon, I.; Bardiès, M.; Chouin, N.; Cartron, G.; Pèlegrin, A.; Azria, D. Clinical radioimmunotherapy--the role of radiobiology. Nat. Rev. Clin. Oncol. 2011, 8, 720–734.
  8. Makvandi, M.; Dupis, E.; Engle, J.W.; Nortier, F.M.; Fassbender, M.E.; Simon, S.; Birnbaum, E.R.; Atcher, R.W.; John, K.D.; Rixe, O.; et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: From Basic Science to Clinical Investigations. Target. Oncol. 2018, 13, 189–203.
  9. Siemann, D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat. Rev. 2011, 37, 63–74.
  10. Mengdi, Q.; Almasan, A.; Gurkan-Cavusoglu, E. Computational analysis of androgen receptor dependent radiosensitivity in prostate cancer. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2016, 2016, 1426–1429.
  11. Rong, C.; Meinert, E.; Hess, J. Estrogen Receptor Signaling in Radiotherapy: From Molecular Mechanisms to Clinical Studies. Int. J. Mol. Sci. 2018, 19, 713.
  12. Klintman, M.; Buus, R.; Cheang, M.C.; Sheri, A.; Smith, I.E.; Dowsett, M. Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. Clin. Cancer Res. 2016, 22, 2405–2416.
  13. Buchholz, T.A.; Stivers, D.N.; Stec, J.; Ayers, M.; Clark, E.; Bolt, A.; Sahin, A.A.; Symmans, W.F.; Hess, K.R.; Kuerer, H.M.; et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002, 8, 461–468.
  14. Beltran, H.; Wyatt, A.W.; Chedgy, E.C.; Donoghue, A.; Annala, M.; Warner, E.W.; Beja, K.; Sigouros, M.; Mo, F.; Fazli, L.; et al. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin. Cancer Res. 2017, 23, 6802–6811.
  15. Lehmusvaara, S.; Erkkilä, T.; Urbanucci, A.; Waltering, K.; Seppälä, J.; Larjo, A.; Tuominen, V.J.; Isola, J.; Kujala, P.; Lähdesmäki, H.; et al. Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J. Pathol. 2012, 227, 336–345.
  16. Severson, T.M.; Nevedomskaya, E.; Peeters, J.; Kuilman, T.; Krijgsman, O.; van Rossum, A.; Droog, M.; Kim, Y.; Koornstra, R.; Beumer, I.; et al. Neoadjuvant tamoxifen synchronizes ERalpha binding and gene expression profiles related to outcome and proliferation. Oncotarget 2016, 7, 33901–33918.
  17. Gill, M.R.; Falzone, N.; Du, Y.; Vallis, K.A. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017, 18, e414–e423.
  18. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
  19. Catalona, W.J. Prostate Cancer Screening. Med. Clin. N. Am. 2018, 102, 199–214.
  20. Mottet, N.; Bellmunt, J.; Bolla, M.; Briers, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.; Henry, A.M.; Joniau, S.; et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part. 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 2017, 71, 618–629.
  21. Litwin, M.S.; Tan, H.J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA 2017, 317, 2532–2542.
  22. Jadvar, H. Targeted Radionuclide Therapy: An Evolution toward Precision Cancer Treatment. AJR Am. J. Roentgenol. 2017, 209, 277–288.
  23. Kluetz, P.G.; Pierce, W.; Maher, V.E.; Zhang, H.; Tang, S.; Song, P.; Liu, Q.; Haber, M.T.; Leutzinger, E.E.; Al-Hakim, A.; et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 2014, 20, 9–14.
  24. Anderson, P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin. Pharmacother. 2006, 7, 1475–1486.
  25. Deshayes, E.; Roumiguie, M.; Thibault, C.; Beuzeboc, P.; Cachin, F.; Hennequin, C.; Huglo, D.; Rozet, F.; Kassab-Chahmi, D.; Rebillard, X.; et al. Radium 223 dichloride for prostate cancer treatment. Drug Des. Dev. Ther. 2017, 11, 2643–2651.
  26. Deng, X.; He, G.; Liu, J.; Luo, F.; Peng, X.; Tang, S.; Gao, Z.; Lin, Q.; Keller, J.M.; Yang, T.; et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev. 2014, 40, 730–738.
  27. Fuller, M.S.; Lee, C.I.; Elmore, J.G. Breast cancer screening: An evidence-based update. Med. Clin. N. Am. 2015, 99, 451–468.
  28. McDonald, E.S.; Clark, A.S.; Tchou, J.; Zhang, P.; Freedman, G.M. Clinical Diagnosis and Management of Breast Cancer. J. Nucl. Med. 2016, 57, 9S–16S.
  29. Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; et al. Molecular portraits of human breast tumours. Nature 2000, 406, 747–752.
  30. Sørlie, T.; Perou, C.M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869–10874.
  31. Sørlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J.S.; Nobel, A.; Deng, S.; Johnsen, H.; Pesich, R.; Geisler, S.; et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100, 8418–8423.
  32. Makki, J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin. Med. Insights Pathol. 2015, 8, 23–31.
  33. Lumachi, F.; Brunello, A.; Maruzzo, M.; Basso, U.; Basso, S.M. Treatment of estrogen receptor-positive breast cancer. Curr. Med. Chem. 2013, 20, 596–604.
  34. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, (Radium RA-223 Dichloride). Available online: (accessed on 19 April 2021).
  35. Coleman, R.; Aksnes, A.K.; Naume, B.; Garcia, C.; Jerusalem, G.; Piccart, M.; Vobecky, N.; Thuresson, M.; Flamen, P. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res. Treat. 2014, 145, 411–418.
  36. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, (Samarium Sm-153 Lexidronam Pentasodium). Available online: (accessed on 19 April 2021).
  37. Niaz, M.J.; Batra, J.S.; Walsh, R.D.; Ramirez-Fort, M.K.; Vallabhajosula, S.; Jhanwar, Y.S.; Molina, A.M.; Nanus, D.M.; Osborne, J.R.; Bander, N.H.; et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist 2020, 25, e477–e895.
  38. Feuerecker, B.; Tauber, R.; Knorr, K.; Heck, M.; Beheshti, A.; Seidl, C.; Bruchertseifer, F.; Pickhard, A.; Gafita, A.; Kratochwil, C.; et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur. Urol. 2021, 79, 343–350.
  39. Kratochwil, C.; Bruchertseifer, F.; Giesel, F.L.; Weis, M.; Verburg, F.A.; Mottaghy, F.; Kopka, K.; Apostolidis, C.; Haberkorn, U.; Morgenstern, A. 225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016, 57, 1941–1944.
  40. Dalm, S.; de Blois, E.; Haeck, J.; Doeswijk, G.; Orlandi, F.; BARBATO, D.; Tedesco, M.; Konijnenberg, M.; De Jong, M. 177Lu-NeoBOMB1 for GRPR-mediated cancer treatment: The effect of peptide mass on efficacy and safety. J. Nucl. Med. 2018, 59, 534.
  41. Kaloudi, A.; Lymperis, E.; Giarika, A.; Dalm, S.; Orlandi, F.; Barbato, D.; Tedesco, M.; Maina, T.; de Jong, M.; Nock, B.A. NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice. Molecules 2017, 22, 1950.
  42. Kurth, J.; Krause, B.J.; Schwarzenböck, S.M.; Bergner, C.; Hakenberg, O.W.; Heuschkel, M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: A radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 123–135.
  43. Dalm, S.U.; Nonnekens, J.; Doeswijk, G.N.; de Blois, E.; van Gent, D.C.; Konijnenberg, M.W.; de Jong, M. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. J. Nucl. Med. 2016, 57, 260–265.
  44. Luo, T.Y.; Cheng, P.C.; Chiang, P.F.; Chuang, T.W.; Yeh, C.H.; Lin, W.J. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann. Nucl. Med. 2014, 29, 52–62.
  45. Huggins, C.; Hodges, C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972, 22, 232–240.
  46. Crawford, E.D.; Heidenreich, A.; Lawrentschuk, N.; Tombal, B.; Pompeo, A.; Mendoza-Valdes, A.; Miller, K.; Debruyne, F.; Klotz, L. Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019, 22, 24–38.
  47. Kumar, S.; Shelley, M.; Harrison, C.; Coles, B.; Wilt, T.J.; Mason, M.D. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst. Rev. 2006, 18, CD006019.
  48. McKay, R.R.; Choueiri, T.K.; Taplin, M.E. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 2013, 73, 1417–1430.
  49. Jones, C.U.; Hunt, D.; McGowan, D.G.; Amin, M.B.; Chetner, M.P.; Bruner, D.W.; Leibenhaut, M.H.; Husain, S.M.; Rotman, M.; Souhami, L.; et al. Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer. N. Engl. J. Med. 2011, 365, 107–118.
  50. Polkinghorn, W.R.; Parker, J.S.; Lee, M.X.; Kass, E.M.; Spratt, D.E.; Iaquinta, P.J.; Arora, V.K.; Yen, W.F.; Cai, L.; Zheng, D.; et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013, 3, 1245–1253.
  51. Ghashghaei, M.; Niazi, T.M.; Heravi, M.; Bekerat, H.; Trifiro, M.; Paliouras, M.; Muanza, T. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. Prostate 2018, 78, 64–75.
  52. Palacios, D.A.; Miyake, M.; Rosser, C.J. Radiosensitization in prostate cancer: Mechanisms and targets. BMC Urol. 2013, 13, 4.
  53. Wong, S.K.; Mohamad, N.V.; Giaze, T.R.; Chin, K.Y.; Mohamed, N.; Ima-Nirwana, S. Prostate Cancer and Bone Metastases: The Underlying Mechanisms. Int. J. Mol. Sci. 2019, 20, 2587.
  54. Nevedomskaya, E.; Baumgart, S.J.; Haendler, B. Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int. J. Mol. Sci. 2018, 19, 1359.
  55. Saad, F.; Carles, J.; Gillessen, S.; Heidenreich, A.; Heinrich, D.; Gratt, J.; Lévy, J.; Miller, K.; Nilsson, S.; Petrenciuc, O.; et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: An international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016, 17, 1306–1316.
  56. Smith, M.; Parker, C.; Saad, F.; Miller, K.; Tombal, B.; Ng, Q.S.; Boegemann, M.; Matveev, V.; Piulats, J.M.; Zucca, L.E.; et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019, 20, 408–419.
  57. Murga, J.D.; Moorji, S.M.; Han, A.Q.; Magargal, W.W.; DiPippo, V.A.; Olson, W.C. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 2015, 75, 242–254.
  58. Hope, T.A.; Truillet, C.; Ehman, E.C.; Afshar-Oromieh, A.; Aggarwal, R.; Ryan, C.J.; Carroll, P.R.; Small, E.J.; Evans, M.J. Ga-68-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J. Nucl. Med. 2017, 58, 81–84.
  59. Moo, T.A.; Sanford, R.; Dang, C.; Morrow, M. Overview of Breast Cancer Therapy. PET Clin. 2018, 13, 339–354.
  60. Draganescu, M.; Carmocan, C. Hormone Therapy in Breast Cancer. Chirurgia 2017, 112, 413–417.
  61. Chargari, C.; Toillon, R.A.; Macdermed, D.; Castadot, P.; Magné, N. Concurrent hormone and radiation therapy in patients with breast cancer: What is the rationale? Lancet Oncol. 2009, 10, 53–60.
  62. Ueno, N.T.; Tahara, R.K.; Saigal, B.; Fujii, T.; Reuben, J.M.; Gao, H.; Lucci, A.; Ibrahim, N.K.; Damodaran, S.; Shen, Y.; et al. Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. J. Clin. Oncol. 2018, 36, 1065.
  63. Mitran, B.; Rinne, S.S.; Konijnenberg, M.W.; Maina, T.; Nock, B.A.; Altai, M.; Vorobyeva, A.; Larhed, M.; Tolmachev, V.; de Jong, M.; et al. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist (177) Lu-DOTAGA-PEG2 -RM26. Int. J. Cancer 2019, 145, 3347–3358.
  64. Morgat, C.; Schollhammer, R.; Macgrogan, G.; Barthe, N.; Vélasco, V.; Vimont, D.; Cazeau, A.L.; Fernandez, P.; Hindié, E. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. PLoS ONE 2019, 14, e0210905.
  65. Morgat, C.; MacGrogan, G.; Brouste, V.; Vélasco, V.; Sévenet, N.; Bonnefoi, H.; Fernandez, P.; Debled, M.; Hindié, E. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1432 Primary Tumors. J. Nucl. Med. 2017, 58, 1401–1407.
  66. Dalm, S.U.; Sieuwerts, A.M.; Look, M.P.; Melis, M.; van Deurzen, C.H.; Foekens, J.A.; de Jong, M.; Martens, J.W. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy. J. Nucl. Med. 2015, 56, 1487–1493.
  67. Seiwert, T.Y.; Salama, J.K.; Vokes, E.E. The concurrent chemoradiation paradigm--general principles. Nat. Clin. Pract. Oncol. 2007, 4, 86–100.
  68. Lajous, H.; Lelièvre, B.; Vauléon, E.; Lecomte, P.; Garcion, E. Rethinking Alkylating(-Like) Agents for Solid Tumor Management. Trends Pharmacol. Sci. 2019, 40, 342–357.
  69. Peters, G.J. Novel Developments in the Use of Antimetabolites. Nucleosides Nucleotides Nucleic Acids 2014, 33, 358–374.
  70. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J.V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol. Ther. 2012, 133, 26–39.
  71. Mihlon, F.T.; Ray, C.E., Jr.; Messersmith, W. Chemotherapy agents: A primer for the interventional radiologist. Semin. Interv. Radiol. 2010, 27, 384–390.
  72. Durand, R.E.; LePard, N.E. Effects of mitomycin C on the oxygenation and radiosensitivity of murine and human tumours in mice. Radiother. Oncol. 2000, 56, 245–252.
  73. Bartelink, H.; Kallman, R.F.; Rapacchietta, D.; Hart, G.A. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother. Oncol. 1986, 6, 61–74.
  74. Nylén, U.; Cekan, E.; Jonasson, G.B.; Lewin, F.; Skog, S. Effects of 5-fluorouracil on cell cycle arrest and toxicity induced by X-irradiation in normal mammalian cells. Cell Prolif. 2001, 34, 85–98.
  75. Seiwert, T.Y.; Salama, J.K.; Vokes, E.E. The chemoradiation paradigm in head and neck cancer. Nat. Clin. Pract. Oncol. 2007, 4, 156–171.
  76. O’Rourke, N.; Roqué I Figuls, M.; Farré Bernadó, N.; Macbeth, F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2010, 18, CD002140.
  77. Kim, J.J.; Tannock, I.F. Repopulation of cancer cells during therapy: An. important cause of treatment failure. Nat. Rev. Cancer 2005, 5, 516–525.
  78. Shapiro, G.I.; Harper, J.W. Anticancer drug targets: Cell cycle and checkpoint control. J. Clin. Invest. 1999, 104, 1645–1653.
  79. Vaupel, P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 2004, 14, 198–206.
  80. Saggar, J.K.; Tannock, I.F. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302. Clin. Cancer Res. 2015, 21, 2107–2114.
  81. Milas, L.; Hunter, N.R.; Mason, K.A.; Milross, C.G.; Saito, Y.; Peters, L.J. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res. 1995, 55, 3564–3568.
  82. Pouget, J.P.; Lozza, C.; Deshayes, E.; Boudousq, V.; Navarro-Teulon, I. Introduction to radiobiology of targeted radionuclide therapy. Front. Med. 2015, 2, 12.
  83. Geldof, A.A.; de Rooij, L.; Versteegh, R.T.; Newling, D.W.; Teule, G.J. Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J. Nucl. Med. 1999, 40, 667–671.
  84. Isaacs, J.T.; Yu, G.W.; Coffey, D.S. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: The MAT LyLu tumor. Invest. Urol. 1981, 19, 20–23.
  85. Sciuto, R.; Festa, A.; Rea, S.; Pasqualoni, R.; Bergomi, S.; Petrilli, G.; Maini, C.L. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial. J. Nucl. Med. 2002, 43, 79–86.
  86. Kelly, M.P.; Lee, S.T.; Lee, F.T.; Smyth, F.E.; Davis, I.D.; Brechbiel, M.W.; Scott, A.M. Therapeutic Efficacy of Lu-177-CHX-A ‘‘-DTPA-hu3S193 Radioimmunotherapy in Prostate Cancer Is Enhanced by EGFR Inhibition or Docetaxel Chemotherapy. Prostate 2009, 69, 92–104.
  87. Hellström, I.; Garrigues, H.J.; Garrigues, U.; Hellström, K.E. Highly Tumor-Reactive, Internalizing, Mouse Monoclonal-Antibodies to Ley-Related Cell-Surface Antigens. Cancer Res. 1990, 50, 2183–2190.
  88. Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 21–26.
  89. Dunne, A.L.; Mothersill, C.; Robson, T.; Wilson, G.D.; Hirst, D.G. Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action. Oncol. Res. 2004, 14, 447–454.
  90. Milas, L. Docetaxel/radiation combinations: Rationale and preclinical findings. Clin. Lung Cancer 2002, 3, S29–S36.
  91. Pradier, O.; Rave-Fränk, M.; Lehmann, J.; Lücke, E.; Boghun, O.; Hess, C.F.; Schmidberger, H. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ). Int. J. Cancer 2001, 91, 840–845.
  92. Hennequin, C.; Giocanti, N.; Favaudon, V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996, 56, 1842–1850.
  93. Lange, R.; ter Heine, R.; van Wieringen, W.N.; Tromp, A.M.; Paap, M.; Bloemendal, H.J.; de Klerk, J.M.; Hendrikse, N.H.; Geldof, A.A. Cytotoxic effects of the therapeutic radionuclide rhenium-188 combined with taxanes in human prostate carcinoma cell lines. Cancer Biother. Radiopharm. 2017, 32, 16–23.
  94. Andre, F.; Zielinski, C.C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol. 2012, 23, 46–51.
  95. Al-Ejeh, F.; Shi, W.; Miranda, M.; Simpson, P.T.; Vargas, A.C.; Song, S.; Wiegmans, A.P.; Swarbrick, A.; Welm, A.L.; Brown, M.P.; et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J. Nucl. Med. 2013, 54, 913–921.
  96. Gibbens-Bandala, B.; Morales-Avila, E.; Ferro-Flores, G.; Santos-Cuevas, C.; Meléndez-Alafort, L.; Trujillo-Nolasco, M.; Ocampo-García, B. (177)Lu-Bombesin-PLGA (paclitaxel): A targeted controlled-release nanomedicine for bimodal therapy of breast cancer. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 105, 110043.
  97. Reubi, J.C.; Wenger, S.; Schmuckli-Maurer, J.; Schaer, J.C.; Gugger, M. Bombesin receptor subtypes in human cancers: Detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin. Cancer Res. 2002, 8, 1139–1146.
  98. Khalil, D.N.; Smith, E.L.; Brentjens, R.J.; Wolchok, J.D. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 2016, 13, 394.
  99. Drake, C.G. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 2010, 10, 580–593.
  100. Emens, L.A. Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Rev. Anticancer Ther. 2012, 12, 1597–1611.
  101. Chakraborty, M.; Wansley, E.K.; Carrasquillo, J.A.; Yu, S.; Paik, C.H.; Camphausen, K.; Becker, M.D.; Goeckeler, W.F.; Schlom, J.; Hodge, J.W. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin. Cancer Res. 2008, 14, 4241–4249.
  102. Gulley, J.L.; Madan, R.A.; Tsang, K.Y.; Arlen, P.M.; Camphausen, K.; Mohebtash, M.; Kamrava, M.; Schlom, J.; Citrin, D. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin. Biol. Ther. 2011, 11, 1409–1418.
  103. Chi, K.H.; Liu, S.J.; Li, C.P.; Kuo, H.P.; Wang, Y.S.; Chao, Y.; Hsieh, S.L. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J. Immunother. 2005, 28, 129–135.
  104. Klug, F.; Prakash, H.; Huber, P.E.; Seibel, T.; Bender, N.; Halama, N.; Pfirschke, C.; Voss, R.H.; Timke, C.; Umansky, L.; et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 2013, 24, 589–602.
  105. Ukidve, A.; Cu, K.; Kumbhojkar, N.; Lahann, J.; Mitragotri, S. Overcoming biological barriers to improve solid tumor immunotherapy. Drug Deliv. Transl. Res. 2021, 1–26.
  106. Martin, J.D.; Cabral, H.; Stylianopoulos, T.; Jain, R.K. Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges. Nat. Rev. Clin. Oncol. 2020, 17, 251–266.
  107. Hu, Z.I.; McArthur, H.L.; Ho, A.Y. The Abscopal Effect of Radiation Therapy: What Is It and How Can. We Use It in Breast Cancer? Curr. Breast Cancer Rep. 2017, 9, 45–51.
  108. Zhou, J.; Wang, G.; Chen, Y.; Wang, H.; Hua, Y.; Cai, Z. Immunogenic cell death in cancer therapy: Present and emerging inducers. J. Cell. Mol. Med. 2019, 23, 4854–4865.
  109. Malamas, A.S.; Gameiro, S.R.; Knudson, K.M.; Hodge, J.W. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Oncotarget 2016, 7, 86937–86947.
  110. Lu, Y.C.; Weng, W.C.; Lee, H. Functional roles of calreticulin in cancer biology. Biomed. Res. Int. 2015, 2015, 526524.
  111. Wieczorek, M.; Abualrous, E.T.; Sticht, J.; Álvaro-Benito, M.; Stolzenberg, S.; Noé, F.; Freund, C. Major Histocompatibility Complex. (MHC) Class. I and MHC Class. II Proteins: Conformational Plasticity in Antigen Presentation. Front. Immunol. 2017, 8, 292.
  112. Czernin, J.; Current, K.; Mona, C.E.; Nyiranshuti, L.; Hikmat, F.; Radu, C.G.; Lückerath, K. Immune-Checkpoint Blockade Enhances (225)Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. J. Nucl. Med. 2021, 62, 228–231.
  113. Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11, 239–253.
  114. Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012, 9, 193–199.
  115. Dietrich, A.; Koi, L.; Zöphel, K.; Sihver, W.; Kotzerke, J.; Baumann, M.; Krause, M. Improving external beam radiotherapy by combination with internal irradiation. Br. J. Radiol. 2015, 88, 20150042.
  116. Nilsson, S.; Franzén, L.; Parker, C.; Tyrrell, C.; Blom, R.; Tennvall, J.; Lennernäs, B.; Petersson, U.; Johannessen, D.C.; Sokal, M.; et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007, 8, 587–594.
  117. Baczyk, M.; Milecki, P.; Pisarek, M.; Gut, P.; Antczak, A.; Hrab, M. A prospective randomized trial: A comparison of the analgesic effect and toxicity of 153Sm radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy (EBRT) among metastatic castrate resistance prostate cancer (mCRPC) patients with painful bone metastases. Neoplasma 2013, 60, 328–333.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback